CD8A and colitis: We observed a modest increase in HMGB1 and increased CD8+IFNγ+ cells during the colitis inflammatory process (DSS and UC) and in the early period after AOM administration, whereas CD8+IFNγ+ cells decreased and CD8+PDL1+ cells increased during carcinogenesis progression.